LEADER 04383oam  2201261zu 450 
001 9910698235503321
005 20251017110057.0
035   $a(CKB)3450000000002075
035   $a(SSID)ssj0000622399
035   $a(PQKBManifestationID)11383848
035   $a(PQKBTitleCode)TC0000622399
035   $a(PQKBWorkID)10642367
035   $a(PQKB)22010915
035   $a(WaSeSS)Ind00030679
035   $a(OCoLC)77638732
035   $a(DNLM)1304422
035   $a(EXLCZ)993450000000002075
100   $a20160829d2007      uy 
101 0 $aeng
135   $aur|||||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aTesting for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs
210 31$a[Place of publication not identified]$cAHRQ$d2007
215   $a1 online resource
225 0 $aEvidence report/technology assessment Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs)
300   $aBibliographic Level Mode of Issuance: Monograph
320   $aIncludes bibliographical references.
410  0$aEvidence report/technology assessment ;$vno. 146.
410  0$aAHRQ publication ;$vno. 07-E002.
606   $aSerotonin uptake inhibitors$xChemotherapy
606   $aCytochrome P-450
606   $aDepression, Mental
606   $aPharmacogenetics
606   $aGenetic Variation
606   $aDepressive Disorder
606   $aSerotonin Agents
606   $aAge Groups
606   $aNeurotransmitter Uptake Inhibitors
606   $aCytochromes
606   $aMixed Function Oxygenases
606   $aHemeproteins
606   $aGenetic Phenomena
606   $aMood Disorders
606   $aPersons
606   $aNeurotransmitter Agents
606   $aOxygenases
606   $aEnzymes and Coenzymes
606   $aProteins
606   $aMolecular Mechanisms of Pharmacological Action
606   $aPhysiological Effects of Drugs
606   $aOxidoreductases
606   $aMental Disorders
606   $aPharmacologic Actions
606   $aAmino Acids, Peptides, and Proteins
606   $aEnzymes
606   $aChemical Actions and Uses
606   $aPolymorphism, Genetic
606   $aCytochrome P-450 Enzyme System
606   $aAdult
606   $aMajor Depressive Disorder
606   $aSelective Serotonin Reuptake Inhibitors
606   $aHealth & Biological Sciences$2HILCC
606   $aPharmacy, Therapeutics, & Pharmacology$2HILCC
615  0$aSerotonin uptake inhibitors$xChemotherapy.
615  0$aCytochrome P-450.
615  0$aDepression, Mental.
615  0$aPharmacogenetics.
615  2$aGenetic Variation.
615  2$aDepressive Disorder.
615  2$aSerotonin Agents.
615  2$aAge Groups.
615  2$aNeurotransmitter Uptake Inhibitors.
615  2$aCytochromes.
615  2$aMixed Function Oxygenases.
615  2$aHemeproteins.
615  2$aGenetic Phenomena.
615  2$aMood Disorders.
615  2$aPersons.
615  2$aNeurotransmitter Agents.
615  2$aOxygenases.
615  2$aEnzymes and Coenzymes.
615  2$aProteins.
615  2$aMolecular Mechanisms of Pharmacological Action.
615  2$aPhysiological Effects of Drugs.
615  2$aOxidoreductases.
615  2$aMental Disorders.
615  2$aPharmacologic Actions.
615  2$aAmino Acids, Peptides, and Proteins.
615  2$aEnzymes.
615  2$aChemical Actions and Uses.
615  2$aPolymorphism, Genetic.
615  2$aCytochrome P-450 Enzyme System.
615  2$aAdult.
615  2$aMajor Depressive Disorder.
615  2$aSelective Serotonin Reuptake Inhibitors.
615  7$aHealth & Biological Sciences
615  7$aPharmacy, Therapeutics, & Pharmacology
676   $a615/.78
702   $aMatchar$b David B.
712 02$aUnited States Agency for Healthcare Research and Quality
712 02$aDuke University Evidence-based Practice Center,
801  0$bPQKB
906   $aBOOK
912   $a9910698235503321
996   $aTesting for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs$93140792
997   $aUNINA